Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe: Lessons for Inferring Generalizability

Drummond, 1992, Issues in the cross-national assessment of health technology, Int J Technol Assess Health Care, 8, 671, 10.1017/S0266462300002361 Drummond, 2001, Transferability of economic evaluation results Office of Health Economics, 2002 NHS Centre for Reviews and Dissemination, 2002 2002 Drummond, 1997 Cook, 2003, Assessing the appropriateness of combining economic data from multinational clinical trials, Stat Med, 22, 1955, 10.1002/sim.1389 Drummond, 2003, Will there ever be a European drug pricing and reimbursement agency?, Euro J Health Econ, 4, 67, 10.1007/s10198-003-0174-5 Willke, 1998, Estimating country-specific cost-effectiveness from multinational clinical trials, Health Econ, 7, 481, 10.1002/(SICI)1099-1050(199809)7:6<481::AID-HEC353>3.0.CO;2-K Aitchison, 1997, Cost-effectiveness of clozapine. A UK clinic-based study, Br J Psychiatry, 171, 125, 10.1192/bjp.171.2.125 Ament, 2000, Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries, Clin Infect Dis, 31, 444, 10.1086/313977 Annemans, 1999, The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis, Anticancer Drugs, 10, 605, 10.1097/00001813-199907000-00013 Arikian, 1994, A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group, Br J Dermatol, 130, S35, 10.1111/j.1365-2133.1994.tb06093.x Ballatori, 1994, Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy, Pharmacoeconomics, 5, 227, 10.2165/00019053-199405030-00006 Bate, 1994, Omeprazole vs ranitidine and cimetidine in reflux oesophagitis, Pharmacoeconomics, 5, 35, 10.2165/00019053-199400053-00007 Berger, 1998, Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective, Eur J Cancer, 34, 1894, 10.1016/S0959-8049(98)00260-3 Beutels, 1996, Costs and benefits of routine varicella vaccination in German children, J Infect Dis, 174, S335, 10.1093/infdis/174.Supplement_3.S335 Biddle, 2002, Modeling the use of triple combination therapy in five countries: nevirapine, zidovudine, didanosine, Value Health, 3, 186, 10.1046/j.1524-4733.2000.33006.x Borghi, 2000, Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK, Eur Psychiat, 15, 378, 10.1016/S0924-9338(00)00506-X Brown, 2000, Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France, Eur Psychiat, 14, 15 Caro, 2000, Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West Scotland Coronary Prevention Study, Acta Cardiol, 55, 239, 10.2143/AC.55.4.2005746 Casciano, 2001, The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy, Int J Clin Pract, 55, 84, 10.1111/j.1742-1241.2001.tb10986.x Copley-Merriman, 1996, Economic value of gemcitabine in non-small cell lung cancer, Semin Oncol, 23, 90 Cunningham, 1993, The real costs of emesis—an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer, Eur J Cancer, 29A, 303, 10.1016/0959-8049(93)90372-M de Pouvourville, 1993, The economic consequences of NSAID-induced gastrointestinal damage, Br J Med Econ, 2, 93 Diez, 1999, A cost benefit analysis of routine varicella vaccination in Spain, Vaccine, 17, 1306, 10.1016/S0264-410X(98)00394-6 Drummond, 1992, Issues in the cross-national assessment of health technology, Int J Technol Assess Health Care, 8, 671, 10.1017/S0266462300002361 Doyle, 2001, A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs, Value Health, 4, 16, 10.1046/j.1524-4733.2001.004001016.x Einarson, 1997, Multinational pharmacoeconomic analysis of topical and oral therapies for onychomycosis, J Dermatolog Treat, 8, 229, 10.3109/09546639709160527 Ekman, 2001, Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial, Pharmacoeconomics, 19, 901, 10.2165/00019053-200119090-00002 Grover, 2001, How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?, Diabetes Care, 24, 45, 10.2337/diacare.24.1.45 Haglund, 2000, The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis, Rheumatology, 39, S51, 10.1093/rheumatology/39.suppl_2.51 Hakkaart-van Roijen, 2001, The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis, Pharmacoeconomics, 19, 599, 10.2165/00019053-200119050-00013 Heaney, 2000, Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries, Epilepsia, 41, S37 Henderson, 1999, The costs of routine eptifibatide use in acute coronary syndromes in Western Europe: an economic substudy of the PURSUIT trial, Eur Heart J Suppl, 1, S35 Hjalte, 1992, Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden, Pharmacoeconomics, 1, 213, 10.2165/00019053-199201030-00009 Hummel, 1997, An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United Kingdom, Pharmacoeconomics, 12, 182, 10.2165/00019053-199712020-00008 Hutton, 1996, A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer, Pharmacoeconomics, 9, S8, 10.2165/00019053-199600092-00004 Iveson, 1999, Irinotecan in second-line treatment of metastatic colorectal cancer. Improved survival and cost-effect compared with infusional 5-FU, Eur J Cancer, 35, 1796, 10.1016/S0959-8049(99)00186-0 Jansen, 1997, Economic evaluation of meloxicam (7.5 mg) versus sustained release diclofenac (100 mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK, Br J Med Econ, 11, 9 Jansen, 2001, Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in Onychomycosis, Pharmacoeconomics, 19, 401, 10.2165/00019053-200119040-00007 Jonsson, 1996, Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S), Eur Heart J, 17, 1001, 10.1093/oxfordjournals.eurheartj.a014994 Jonsson, 1995, Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia, Acta Psychiatr Scand, 92, 199, 10.1111/j.1600-0447.1995.tb09568.x Jonsson, 1999, The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model, Clin Ther, 21, 1230, 10.1016/S0149-2918(00)80025-9 Kendrick, 2000, Long-term treatment of multiple sclerosis with interferon-beta may be cost effective, Pharmacoeconomics, 18, 45, 10.2165/00019053-200018010-00005 Kobelt, 2000, Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis, Int J Technol Assess Health Care, 16, 768, 10.1017/S0266462300102041 Launois, 1996, A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine, Pharmacoeconomics, 10, 504, 10.2165/00019053-199610050-00008 Lee, 1998, Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost, Br J Cancer, 77, 1294, 10.1038/bjc.1998.216 Levy-Piedbois, 2000, Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer, Ann Oncol, 11, 157, 10.1023/A:1008358411251 Levy, 1998, A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study, Cardiovasc Drugs Ther, 12, 301, 10.1023/A:1007773901631 Lindgren, 1994, Omeprazole vs ranitidine in reflux oesophagitis in Sweden, Pharmacoeconomics, 5, 27, 10.2165/00019053-199400053-00006 Lorenzoni, 1998, Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups, Eur Heart J, 19, 1518, 10.1053/euhj.1998.1092 Malek, 1999, A cost minimisation analysis of cardiac failure treatment in the UK using CIBIS trial data. Cardiac Insufficiency Bisoprolol Study, Int J Clin Pract, 53, 19, 10.1111/j.1742-1241.1999.tb11654.x Mantovani, 1998, Captopril in the management of patients after acute myocardial infarctions. A cost effectiveness analysis in Italy, Pharmacol Res, 37, 345, 10.1006/phrs.1998.0297 Mapelli, 1994, Economic evaluation of lenograstim (glycosylated rHuG-CSF) in the treatment of inflammatory breast cancer for Germany and Italy, Pharmacoeconomics, 6, S27, 10.2165/00019053-199400062-00006 Marchetti, 1999, Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement, Haematologica, 84, 730 Martens, 1989, Cost effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin versus cholestyramine, Am J Med, 87, S54, 10.1016/S0002-9343(89)80600-X Menzin, 1996, A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis, Int J Technol Assess Health Care, 12, 52, 10.1017/S0266462300009387 Michel, 1996, Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands, Eur Heart J, 17, 731, 10.1093/oxfordjournals.eurheartj.a014940 Mol, 1999, Treatment of tubal pregnancy in the Netherlands: an economic comparison of systemic methotrexate administration and laparoscopic salpingostomy, Am J Obstet Gynecol, 181, 945, 10.1016/S0002-9378(99)70330-3 Ojeda, 1999, A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults, Bone Marrow Transplant, 24, 601, 10.1038/sj.bmt.1701972 Parkin, 2000, Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life, J Neurol Neurosurg Psychiatry, 68, 144, 10.1136/jnnp.68.2.144 Peeters, 1998, Economic evaluation of Neoral versus Sandimmune maintenance therapy for de novo liver transplant patients: results from an International Randomized Controlled Trial. Milton Study Group, Transplant Proc, 30, 1838, 10.1016/S0041-1345(98)00450-3 Percudani, 1999, Health care costs of therapy-refractory schizophrenic patients treated with clozapine: a study in a community psychiatric service in Italy, Acta Psychiatr Scand, 99, 274, 10.1111/j.1600-0447.1999.tb07225.x Pinto, 2001, Cost effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries, Pharmacoeconomics, 19, 255, 10.2165/00019053-200119030-00004 Robin, 1998, Methotrexate provides significant cost savings for the treatment of unruptured extopic pregnancy, Clin Drug Invest, 15, 405, 10.2165/00044011-199815050-00005 Schadlich, 1998, Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany, Pharmacoeconomics, 13, 147, 10.2165/00019053-199813010-00014 Severo, 1995, Cost effectiveness of hepatitis A prevention in France, Pharmacoeconomics, 8, 46, 10.2165/00019053-199508010-00007 Shear, 1998, Pharmacoeconomic analysis of topical treatments for tinea infections, Int J Dermatol, 37, 64, 10.1046/j.1365-4362.1998.00089.x Simpson, 1994, Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/microliters in 5 European countries, Pharmacoeconomics, 6, 553, 10.2165/00019053-199406060-00008 Stalhammar, 1999, Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease, Pharmacoeconomics, 16, 483, 10.2165/00019053-199916050-00006 Stewart, 1998, Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil, Int J Geriatr Psychiatry, 13, 445, 10.1002/(SICI)1099-1166(199807)13:7<445::AID-GPS794>3.0.CO;2-E Svarvar, 2000, Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway, Rheumatology, 39, S43, 10.1093/rheumatology/39.suppl_2.43 Szucs, 1999, The cost-effectiveness of low-molecular-weight heparin vs unfractionated heparin in general and orthopaedic surgery: an analysis for the German healthcare system, Pharmacol Res, 40, 83, 10.1006/phrs.1999.0479 Tormans, 1992, Cost-effectiveness analysis of hepatitis A prevention in travellers, Vaccine, 10, S88, 10.1016/0264-410X(92)90554-W Willke, 1998, Estimating country-specific cost-effectiveness from multinational clinical trials, Health Econ, 7, 481, 10.1002/(SICI)1099-1050(199809)7:6<481::AID-HEC353>3.0.CO;2-K